The Big Money Show panel discusses President Donald Trump’s drug tariff strategy.
Eli Lilly announced a significant investment of $5 billion for a manufacturing facility in Virginia. This decision comes as the pharmaceutical giant aims to boost its domestic production in light of possible tariffs.
The new facility is expected to create 650 well-paying jobs along with 1,800 construction positions at West Creek Business Park in Goochland County, Virginia. It will focus on producing pharmaceutical ingredients for treatments related to cancer, autoimmune diseases, and other advanced therapies.
This announcement marks an expansion from their initial plan for a $2.1 billion facility, which was intended to generate 468 jobs.
“This investment in Virginia underscores the commitment of the U.S. to innovation and manufacturing, leading to the creation of quality jobs, strengthening communities, and advancing the health and well-being of Americans nationwide,” said Eli Lilly CEO David Ricks. “By enhancing our domestic capabilities, we’re ensuring a reliable supply chain that meets current patient needs while paving the way for future groundbreaking medications.”
Trump takes key prescription drugs and cancels Walmart deals
Virginia Governor Glenn Youngkin expressed gratitude for Eli Lilly’s commitment, stating, “Lilly is one of the world’s foremost innovators, and we appreciate your significant investment in Virginia.”
“By enhancing our manufacturing here in the U.S., we can fortify Virginia’s economy, secure our essential drug supply chain, and lead the industry in innovation for generations to come,” Youngkin added.
| Ticker | safety | last | change | change % |
|---|---|---|---|---|
| lly | Eli Lilly & co. | 748.19 | -7.20 |
-0.95% |
Johnson & Johnson invests $20 billion in U.S. manufacturing, creating new jobs
Pharmaceutical companies are increasing their investments in U.S. manufacturing facilities under President Donald Trump’s administration. Rather than relying heavily on imports, there’s a push to produce more medicines domestically.
Trump has warned of potential customs duties on drugs, suggesting these could begin small but escalate to as high as 250% to boost U.S. production.
Earlier this year, Eli Lilly revealed plans to invest at least $27 billion in four new U.S. manufacturing sites as a strategy against potential tariffs on drug imports.
Reuters contributed to this report.
